OR = odds ratio, GEE = generalized estimating equation. a GEE logistic regression analysis with hospital clusters.
Objectives: Clinical guidelines recommend norepinephrine as initial vasopressor of choice for septic shock, with dopamine suggested as an alternative vasopressor in selected patients with low risk of tachyarrhythmias and absolute or relative bradycardia. We sought to determine practice patterns and outcomes associated with vasopressor selection in a large, population-based cohort of patients with septic shock that allows for assessment of outcomes in clinically important subgroups. Design: We performed a retrospective cohort study to determine factors associated with choice of dopamine as compared with norepinephrine as initial vasopressor for patients with septic shock. We used propensity score matching to compare risk of hospital mortality based on initial vasopressor. We performed multiple sensitivity analyses using alternative methods to address confounding and hospital-level clustering. We investigated interaction between vasopressor selection and mortality in clinical subgroups based on arrhythmia and cardiovascular risk. Setting: Enhanced administrative data (Premier, Charlotte, NC) from 502 U.S. hospitals during the years 2010-2013. Subjects: A total of 61,122 patients admitted with septic shock who received dopamine or norepinephrine as initial vasopressor during the first 2 days of hospitalization. Interventions: None. Measurements and Main Results: Norepinephrine (77.6%) was the most frequently used initial vasopressor during septic shock. Dopamine was preferentially selected by cardiologists, in the Southern United States, at nonteaching hospitals, for older patients with more cardiovascular comorbidities and was used less frequently over time. Patients receiving dopamine experienced greater hospital mortality (propensity-matched cohort: n = 38,788; 25% vs 23.7%; odds ratio, 1.08; 95% CI, 1.02-1.14). Sensitivity analyses showed similar results. Subgroup analyses showed no evidence for effect modification based on arrhythmia risk or underlying cardiovascular disease. Conclusions: In a large population-based sample of patients with septic shock in the United States, use of dopamine as initial vasopressor was associated with increased mortality among multiple clinical subgroups. Areas where use of dopamine as initial vasopressor is more common represent potential targets for quality improvement intervention. (Crit Care Med 2015; 43:2141-2146) Key Words: clinical practice patterns; dopamine; norepinephrine; septic shock; vasopressor agents S eptic shock is an immediately life-threatening manifestation of infection characterized by loss of adequate endorgan perfusion. Septic shock affects approximately 73 per 100,000 U.S. adults (1) with a rising prevalence; average case-fatality rates are 20-30% (1) (2) (3) . Approximately one half of the patients with sepsis and evidence of inadequate tissue perfusion have hemodynamic collapse unresponsive to adequate fluid resuscitation requiring the use of vasopressor medications (3, 4) . The vasopressors most frequently used initially to improve hemodynamics during septic shock, norepinephrine and dopamine, have differing physiologic profiles. Depending on dose, dopamine has stronger β 1 -receptor agonist properties and results in relatively increased cardiac chronotropic and inotropic response with increased cardiac output; norepinephrine has stronger α 1 -agonist effects with more potent peripheral vasoconstriction (5) .
Results of a randomized controlled trial including 1,044 patients with septic shock in Europe showed an increase in new arrhythmias with the use of dopamine as compared with norepinephrine (6) . A subsequent meta-analysis of six trials including 1,408 patients demonstrated increased mortality for dopamine as compared with norepinephrine (7) . As a result, norepinephrine emerged as the guideline-recommended first-line vasopressor of choice during septic shock, with use of dopamine suggested as an alternative in selected patients (e.g., patients with low risk of tachyarrhythmias and absolute or relativebradycardia) (4). However, outcomes associated with vasopressor choice in subgroups of patients with septic shock, such as those with low risk of arrhythmia, are unclear.
Further, knowledge gaps exist regarding utilization patterns and patient outcomes associated with choice of vasopressors for septic shock in the United States. Improved understanding of demographics, clinical characteristics, hospital factors, and temporal trends associated with selection of initial vasopressor during septic shock may inform efforts to target implementation of current guidelines. Comparing effectiveness of dopamine and norepinephrine in a large, population-based cohort may reveal important insights regarding real-world effectiveness and allow for the assessment of clinical outcomes among clinical subgroups of patients with septic shock in whom guidelines continue to suggest dopamine (e.g., patients at low risk of arrhythmias). We explored practice patterns and patient outcomes associated with initial choice of vasopressor therapy in a large, population-based cohort of patients hospitalized with septic shock in the United States between 2010 and 2013.
MATERIALS AND METHODS

Patient Sample
We performed a retrospective cohort study among patients with septic shock using the Premier (Premier, Charlotte, NC) enhanced administrative database. Premier data include standard hospital discharge files and date-stamped pharmacy, laboratory, and diagnostics billing information from over 500 hospitals across all geographic regions of the United States, accounting for approximately 20% of U.S. hospitalizations. We identified patients admitted with septic shock using previously validated methods including patients with a diagnosis of sepsis or septic shock (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/B333) (8, 9) who received norepinephrine or dopamine during the first 2 days of hospitalization. We excluded patients who received more than one vasopressor on the initial day of vasopressor administration due to inability to distinguish the initial vasopressor choice. Patients transferred from another hospital were excluded as there was no documentation of initial vasopressor. We also excluded patients with missing covariates and patients with nonphysician or psychiatric attending specialties. Because of our focus on norepinephrine and dopamine, we excluded patients who received less frequently used initial vasopressors phenylephrine (n = 11,999; 14%), vasopressin (n = 747; 1%), and epinephrine (n = 1,052; 1.4%).
Vasopressor Exposure
We identified vasopressor utilization from pharmacy billing files. We characterized initial vasopressor exposure as the first vasopressor initiated during the first 2 days of hospitalization in order to attenuate potential bias from unmeasured changes in clinical status or severity of illness between time of admission and receipt of each vasopressor.
Covariates
From the Premier database, we identified year of hospitalization, patient demographics, hospital characteristics, attending physician specialty, location of admission, and use of intensive care. We characterized comorbid conditions (10) (11) (12) , acute organ failures that were present at admission (9, 13) , and site of infection (14) using diagnosis code algorithms (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/B333).
Outcomes
We identified factors associated with choice of norepinephrine or dopamine as first vasopressor. We also compared hospital mortality between patients who received dopamine versus norepinephrine as initial vasopressor during septic shock.
Statistical Analysis
Full details of statistical analysis are included in the supplemental methods (Supplemental Digital Content 1, http:// links.lww.com/CCM/B333). We used SAS version 9.4 (Cary, NC) for all analyses, with an α threshold of 0.05. Study procedures were approved by the Boston University Medical Campus Institutional Review Board.
We report continuous variables using means and sds or median and interquartile range depending on distribution and categorical variables as percentages. We evaluated differences in baseline characteristics using standardized differences with a threshold of 0.2 (i.e., the characteristic of interest accounts for 1% of the variance in vasopressor use); conventional p values may show clinically insignificant between-group statistical differences when sample size is large (15) . Using information from all measured covariates, we constructed a nonparsimonious logistic regression model to calculate the probability of receiving dopamine or norepinephrine. We used a propensity scorebased approach to attenuate confounding by observed covariates (16) . To analyze the association between vasopressor choice and mortality, we matched patients using a 1:N match structure based on nearest propensity score in a hierarchical 8-to-1 digit match, without replacement or incomplete matches. We then used conditional logistic regression to compare hospital mortality between patients who received dopamine or norepinephrine (17) and Kaplan-Meier curves to visually demonstrate outcomes, censoring observation time at hospital discharge. Finally, we estimated the proportion of septic shock-related deaths attributable to initial vasopressor choice (population attributable fraction).
We performed a number of sensitivity analyses to explore the robustness of our primary analysis (supplemental methods, Supplemental Digital Content 1, http://links.lww.com/ CCM/B333).
Differences in clinical subgroups were tested using tests of multiplicative interaction in conditional logistic regression analysis among our primary propensity score-matched sample (supplemental methods, Supplemental Digital Content 1, http://links.lww.com/CCM/B333). Surviving Sepsis Campaign
Guidelines suggest use of dopamine as an alternative vasopressor among patients with septic shock only in highly selected patients patients with low risk of tachyarrhythmias and absolute or relative bradycardia (4) . We hypothesized that younger patients and those without a history of atrial fibrillation may have lower arrhythmia risk and, along with patients who have a history of heart failure, may experience better outcomes associated with use of dopamine during septic shock.
RESULTS
Among 121,786 patients with sepsis present at admission who received a vasopressor at any time during hospitalization, we identified 61,122 eligible patients with septic shock who received dopamine or norepinephrine (Fig. 1) . Patients were on average 68 ± 15.3 years, 51.3% were women, and 71.1% were white, with average hospital mortality of 24.4%. A greater proportion of patients with septic shock received norepinephrine (77.6%) as compared with dopamine (22.4%) as initial vasopressor. Baseline clinical variables stratified by initial vasopressor choice are shown in Supplemental Table 2 (Supplemental Digital Content 1, http://links.lww.com/CCM/ B333). In multivariable analysis, hospital or physician factors associated with use of dopamine included Southern U.S. geographic location, nonteaching hospital status, and cardiology provider specialty. Patient factors associated with use of dopamine included older age, a history of heart failure, valvular disease, coronary arterial disease, or renal impairment and no history of atrial fibrillation, venous thromboembolic disease, or cancer. Patients receiving initial dopamine also had fewer acute organ failures, less need for mechanical ventilation at admission, and a lower prevalence of sepsis resulting from pneumonia or gastrointestinal sources. Dopamine was used less frequently over time ( Table 1) .
Prior to propensity score matching, patients receiving norepinephrine as initial vasopressor had unadjusted in-hospital mortality of 24.5%, similar to patients receiving dopamine (23.9%; p = 0.16). Among patients who received dopamine and norepinephrine, propensity score matching resulted in similar distribution of propensity scores (Supplemental Fig. 1 Table  2 , Supplemental Digital Content 1, http://links.lww.com/CCM/ B333). After matching patients based on the propensity score, patients who received dopamine experienced greater hospital mortality as compared with patients receiving norepinephrine (n = 38,788; 25% vs 23.7%; odds ratio, 1.08; 95% CI, 1.02-1.14) (Fig. 2) . An estimated 1.7% of septic shock-related deaths may be attributable to use of dopamine as initial vasopressor. Additional sensitivity analyses showed similar results to the matched cohort, with initial dopamine use associated with increased hospital mortality among patients with septic shock ( Table 2) .
Analyses examining whether clinical outcomes differed by subgroups with differing risk for arrhythmias showed effect estimates consistent with the main outcome: no subgroup showed improved outcomes with use of dopamine ( Fig. 3) . 
DISCUSSION
We characterized the practice patterns of initial vasopressor choice and explored the "real-world" effectiveness of norepinephrine as compared with dopamine in a representative cohort of more than 60,000 patients hospitalized with septic shock in the United States. We found high rates of norepinephrine use as initial vasopressor, three-fold more common than dopamine, with increasing use of norepinephrine over time.
Dopamine was more likely to be selected by cardiologists, in the Southern United States, at nonteaching hospitals, and for older patients with more cardiovascular comorbidities and fewer acute organ failures. After adjusting for baseline differences, our results showed an association between the use of dopamine and increased mortality during septic shock as compared with norepinephrine. We did not find evidence for a mortality benefit of dopamine in any subgroup studied, including patients who may be at lower risk of arrhythmia. Based on our results, hospital case fatality may be reduced by approximately 1.7% if clinicians currently using dopamine switched to initial use of norepinephrine during septic shock. The preferential use of norepinephrine for septic shock in the United States is in accordance with clinical practice guidelines and similar to findings observed in a European multicenter cohort study where norepinephrine use was four-fold more common than dopamine (18) . Our findings of increased mortality associated with dopamine use are also consistent with those from a meta-analysis of clinical trials by De Backer et al (7) , which showed similar effect estimates to our study. Our results expand upon efficacy trials by demonstrating increased effectiveness of norepinephrine over dopamine during septic shock in a large (n = 61,122) population-based, real-world sample.
Evidence supporting the current Surviving Sepsis Campaign suggestion for dopamine as an alternative initial vasopressor in patients with "low risk of tachyarrhythmias and absolute or relative bradycardia" is low (grade 2C) (4). Our findings provide novel evidence that does not support use of dopamine among a subgroup of patients with low risk for arrhythmias. We found no strong evidence for effect modification by clinical subgroups with different arrhythmia risks. If replicated, our findings suggesting norepinephrine as the initial vasopressor of choice among all patients with septic shock may potentially be used to simplify the message of future guidelines.
Increasing use of norepinephrine for patients with septic shock provides evidence for uptake of clinical practice guidelines. However, we also identify areas in which dopamine use is more likely, providing potential targets for focused education, implementation training, and quality improvement interventions. Our findings add novel evidence showing differential management strategies between clinical specialties for patients with septic shock. Cardiologists were the least likely to select norepinephrine as initial vasopressor, despite the probability that patients with cardiac disease may have higher risk of arrhythmias, supporting recent calls by the American Heart Association for further training of cardiologists in noncardiac critical care (19) . In addition, we identified teaching hospitals as almost 50% more likely to use norepinephrine as initial vasopressor during septic shock, suggesting slower uptake of guidelines at nonteaching hospitals. Large regional variations in sepsis care among countries have previously been described (1), but variation in sepsis-specific practice patterns within the United States was unclear. Our findings of lower use of norepinephrine in the Southern United States are especially intriguing in light of previous research, showing that sepsis mortality is greatest in the Southern states (20) . Further studies are needed to assess whether targeting improvement efforts to areas of lower evidence uptake reduces mortality.
Our study had limitations warranting discussion. As with all observational studies, unmeasured confounding cannot be excluded. For example, we were unable to directly measure correlation between vasopressor choice and other guidelinerecommended therapy, such as earlier antibiotics or volume resuscitation. However, we obtained similar results performing multiple sensitivity analyses to address measured confounding, included hospitals as clusters to account for correlated care practices within a hospital, and used an instrumental variable analysis meant to attenuate unmeasured confounders. Sensitivity analyses using traditional multivariable-adjusted regression did not show a statistically significant mortality difference between vasopressors, but standard multivariable models are more likely to produce biased estimates than propensity score-based models upon which our primary analyses were based, and inclusion of multiple covariates may have diminished power to detect a statistically significant difference (16) . Our results should not be generalized to patients who received multiple simultaneous vasopressors, who were excluded from our analysis. Additionally, we were unable to assess differences in outcomes by vasopressor dosage, duration of use, or assess long-term outcomes.
CONCLUSIONS
We have identified a real-world mortality benefit associated with use of norepinephrine when compared with dopamine in a large, population-based study of patients with septic shock in the United States. We did not find any clinical subgroup in which dopamine appeared to improve mortality outcomes; a finding that does not support current Surviving Sepsis Campaign Guideline suggestions that dopamine may be used when arrhythmia risk is low. In addition, our results demonstrate specific areas in which dopamine as initial vasopressor during septic shock is more common, where performance improvement interventions may be most efficiently targeted.
